Bayer stock heads into the open after a Barclays upgrade-fueled advance

At the close on September 9, 2026, Bayer stock hovered around the EUR 49 mark on Xetra after a strong year-to-date gain of about 33.0 percent. The shares drew support from a fresh Barclays price-target increase and deleveraging progress, setting the tone ahead of today’s session.

Bayer stock closed around EUR 49 on Xetra on September 9, 2026, with the shares carrying a year-to-date gain of roughly 33.0 percent in euro terms and trading near recent highs for the group. In the same period, the stock’s performance outpaced the broader DAX 40, underscoring that investors have rewarded Bayer’s progress on cash flow and balance sheet repair.

September 9, 2026 in numbers

Bayer AG (ISIN DE000BAY0017) traded around EUR 49 on Xetra on September 9, 2026 after data from German market overviews showed the shares near EUR 49.12 in midday action, representing an intraday loss of about 0.6 percent compared with the prior close, while still reflecting a gain of roughly 33.0 percent since the start of 2026. According to an overview from Ad-hoc-news on September 9, 2026, the stock traded around the EUR 49 mark with intraday fluctuations roughly between EUR 49.00 and EUR 49.33, illustrating a relatively tight range at elevated levels for the year.

In the same report, Ad-hoc-news noted that Barclays raised its price target for Bayer stock from EUR 60 to EUR 70 while reiterating an Overweight rating, placing the new target roughly 42 percent above a recent closing level of EUR 49.33 and highlighting the bank’s confidence in the deleveraging strategy. The same coverage cited that Bayer’s shares had closed at EUR 49.21 on September 8, 2026, unchanged on the day, implying that the roughly EUR 49 level now serves as a reference mark for the upgraded analyst view. The index comparison in the report described Bayer as one of the stronger names in the DAX 40 on a year-to-date basis, suggesting that the stock’s recovery has outpaced many domestic peers.

Regulatory milestones and events today

Today, Bayer is in focus after the U.S. Food and Drug Administration granted accelerated approval to HYRNUO, also known as sevabertinib, as a first-line targeted therapy for adult patients with HER2-mutated non-squamous non-small cell lung cancer following Priority Review and Breakthrough Therapy Designation. As Las Vegas Sun reported on September 10, 2026, Bayer announced that HYRNUO received accelerated approval from the FDA based on objective response rate and duration of response data, adding a new oral tyrosine kinase inhibitor option to the company’s oncology portfolio. In addition, Bayer highlighted the start of a global Phase II clinical trial for BAY 3670549, a selective GIRK4 inhibitor for atrial fibrillation, which was disclosed on September 9, 2026 and is designed to explore a novel mechanism to stabilize cardiac electrical activity, according to a company release relayed by Las Vegas Sun. These regulatory and pipeline updates, together with the recent Barclays upgrade, provide several potential catalysts for Bayer stock as trading resumes today without yet reflecting any intraday price reaction ahead of the Xetra open.